# SEC Form 4

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

6	OMB Number:	3235-0287								
6	Estimated average burden									
1	nours per response:	0.5								

Instruction 1(b).			Filed pursuant to Section 16(a) of the Securities Exchange Act of 1 or Section 30(h) of the Investment Company Act of 1940	934	nours per	response: 0.5		
1. Name and Addre Foley Todd	ess of Reporting	Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Repare Therapeutics Inc.</u> [ RPTX ]		ationship of Reporting P < all applicable) Director	erson(s) to Issuer 10% Owner		
(Last) C/O MPM CAP		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/09/2021		Officer (give title below)	Other (specify below)		
450 KENDALL STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Fil	int/Group Filing (Check Applicable		
(Street)				X	Form filed by One Re	eporting Person		
CAMBRIDGE	ABRIDGE MA 02142				Form filed by More th Person	an One Reporting		
(City)	(State)	(Zip)						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Shares	07/09/2021		S <sup>(1)</sup>		1,792 <sup>(2)</sup>	D	\$33.06 <sup>(3)</sup>	2,268,195	Ι	See Footnote <sup>(4)</sup>
Common Shares	07/12/2021		S <sup>(1)</sup>		25,246 <sup>(5)</sup>	D	\$33.58 <sup>(6)</sup>	2,242,949	Ι	See Footnote <sup>(7)</sup>
Common Shares	07/12/2021		S <sup>(1)</sup>		313 <sup>(8)</sup>	D	\$34.1 <sup>(9)</sup>	2,242,636	Ι	See Footnote <sup>(10)</sup>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispo of (D	r osed ) 7. 3, 4	Expiration Date (Month/Day/Year)		Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

### **Explanation of Responses:**

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.

2. The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014") and 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014").

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$32.95 to \$33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 70,952 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

5. The shares were sold as follows: 24,408 by BV 2014 and 838 by AM BV2014.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.05 to \$34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B) and 70,114 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

8. The shares were sold as follows: 303 by BV 2014 and 10 by AM BV2014.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.055 to \$34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

10. The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B) and 70,104 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Remarks:

## /s/ Todd Foley

\*\* Signature of Reporting Person

07/13/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.